Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It

기사 요약

Sanofi beats Q3 earnings consensus on Dupixent growth, raises 2026 guidance, and outlines long-term plans to handle upcoming patent expirations.